Blocking RAS oncoproteins, a critical node of cancer

RAS pathways are frequently activated in many cancers. Our mission is to develop novel inhibitors of RAS signaling to provide patients with additional therapeutic options in the future.

Recognizing that cancers adapt while patients are undergoing cancer treatment, we strive to develop broadly acting agents that can be used as monotherapies and in combinations.